Chinese pharma group combining generics and APIs with an overseas biologics unit that won FDA approval for a neutropenia drug.
Chinese pharma group combining generics and APIs with an overseas biologics unit that won FDA approval for a neutropenia drug.
Splits between generics and ingredients sold in volume and a long-acting biologic, Ryzneuta, which US partner Acrotech Biopharma sells after FDA approval in 2023, so licensing payments and royalties may become the higher-value stream.
In one line: A generics maker with one Amgen-style biologic win.
Moat: narrow (IP / patents). Rare Chinese-originated biologic with US FDA approval and an outside licensing partner.
Headquarters: Hefei, China · Employees: 4,221
Size Yifan Pharmaceutical (002019.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.57B, the 1458th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.80 on 18 Nov 2026.
Performance Over six months the shares fell 19.2%, against -7.7% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue fell 5.1% over the last twelve months (peer median +6.8%); the operating margin is 8.2% (peer median 12.4%).
Valuation It trades at 25.6× forward earnings against a peer median of 29.0× (6th cheapest of 14).
Capital Return on invested capital runs 2.1 points below its cost of capital (7.0% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.93B | CN¥5.11B | CN¥5.13B | CN¥4.04B | CN¥3.82B |
| Revenue growth | — | 0% | +27% | +6% | — |
| Gross profit | CN¥2.51B | CN¥2.32B | CN¥2.35B | CN¥1.85B | CN¥1.78B |
| EBITDA | n/a | CN¥804M | CN¥735M | CN¥289M | CN¥408M |
| Net income | CN¥311M | CN¥402M | CN¥386M | -CN¥551M | CN¥191M |
| Free cash flow | -CN¥27.3M | -CN¥101M | CN¥15.2M | -CN¥151M | -CN¥68.2M |
| Capital expenditure | CN¥593M | CN¥559M | CN¥628M | CN¥504M | CN¥542M |
| Total debt | CN¥2.96B | CN¥2.36B | CN¥2.29B | CN¥2.00B | CN¥2.18B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Yifan Pharmaceutical 002019.SZ | $1.57B | -19% | -5% | 8% | 25.6× | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 18.3× | 1.6% |
| Kyowa Kirin 4151.T | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002019.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.4% | -3.8% | 10th lowest of 21 |
| 6-month return | -19.2% | -7.7% | 6th lowest of 20 |
| Distance from 52-week high | -40.3% | -29.4% | 8th lowest of 21 |
| Revenue growth (TTM) | -5.1% | +6.8% | 7th lowest of 20 |
| Operating margin | 8.2% | 12.4% | 6th lowest of 20 |
| Forward P/E | 25.6× | 29.0× | 6th cheapest of 14 |
| ROIC minus cost of capital | -2.1 pp | +1.2 pp | 9th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | n/a | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 58.9× | 36.3% | +16.6% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |